Alexion trials rare disease drug Ultomiris in severe COVID-1...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients.

Alexion’s biosimilar-blocking EU patent play for Soliris fai...

Alexion’s Soliris follow-up Ultomiris snares EU approval

Seven future blockbuster drugs to look out for in 2019

AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023.